Pharm

Enlicitide

search

Enlicitide, Lipfendra

  • See Also
  1. PCSK9 Inhibitor
  2. AntiHyperlipidemic
  3. Hyperlipidemia Management
  4. Inclisiran
  5. Alirocumab
  6. Evolocumab
  7. Lerodalcibep
  • Indications
  1. Severe Familial Hypercholesterolemia (e.g. LDL Cholesterol >190 mg/dl)
    1. Enlicitide is the first oral PCSK9 Inhibitor as of 2026 (others in class are Parenteral)
  • Mechanism
  1. See PCSK9 Inhibitor
  2. Human Monoclonal Antibody (PCSK9 Inhibitor)
  • Medications
  1. Enlicitide (Lipfendra) tablets
    1. Store at room Temperature in original container with desiccant (tablets are moisture sensitive)
    2. Cost/year: $3800 at time of release in 2026 (50% of injectable PCSK9 Inhibitors)
  • Dosing
  1. Enlicitide (Lipfendra) 20 mg orally daily
  2. Take with water or plain Coffee or tea (no additives)
    1. Delay other food or beverage until at least 30 minutes after taking Enlicitide
  3. When transitioning from injectable PCSK9 Inhibitor
    1. First dose of Enlicitide should be on the day when the scheduled injectable would have been due
  • Efficacy
  1. LDL Cholesterol lowered 60% when added to a Statin (at 20 mg dose, similar to injectable PCSK9 Inhibitors)
  2. Cardiovascular outcome studies not available at time of release in 2026
  • Resources
  1. Enlicitide (Lipfendra)
    1. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=100ec543-fbd0-44fc-b740-db9cdff39145
  • References
  1. (2026) Presc Insights 33(9): 5-6